Meet The Surgeons Taking On The Silent Epidemic Of Chronic Pain, With Advocates Like Billie Eilish And Kathy Bates Calling For Change
Chronic pain is a worldwide epidemic that disproportionately affects women. These surgeons have found innovative solutions - ...
Pharmabiz14d
Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain
Suzetrigine is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. “Today’s approval is a historic ...
Hosted on MSN14d
Non-Opioid Pain Medication Journavx Gets FDA Approval
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain ... also allowed to take ...
BMJ14d
Mortality associated with moderate and severe mitral regurgitation in 608 570 men and women undergoing echocardiography
Results There were 319 808 men and 288 762 women aged 62.1±18.5 years, of whom 456 989 (75.1%), 102 950 (16.9%), 38 504 (6.3%) and 10 127 (1.7%) individuals had no/trivial, mild, moderate and severe ...
Ars Technica15d
FDA approves first non-opioid pain medicine in more than 20 years
trumpeted the approval as a "historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe acute pain each year. ... [W]e have the opportunity to ...
Human Rights Watch15d
“You Can Feel That the Land is in Pain”
“It’s almost like you can feel that the land is in pain, and you are carrying that pain in your body as well.” The destruction of parts of Ritidian Point weigh heavily on her and other Chamorro.
Putnam Daily Voice15d
FDA Approves First Non-Opioid Pain Drug In 20+ Years—Developed By Boston Drugmaker
"Today's approval is a historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe ... greater pain relief compared to those given a placebo.
PipelineReview.com15d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. “Today’s approval is a historic milestone ...
AFP15d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. This press release features multimedia.
Healio15d
FDA approves nonopioid Journavx for moderate to severe acute pain
Perspective from Anita Gupta, DO, PharmD, MPP, GMP, FASA The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a press release.
Pharm Exec15d
FDA Approves Vertex Pharmaceuticals’ First-in-Class Non-Opioid Journavx for Moderate-to-Severe Acute Pain
The FDA has approved Vertex Pharmaceuticals’ Journavx (suzetrigine), a first-in-class, non-opioid pain signal inhibitor for adults with moderate-to-severe acute pain. According to the company, the ...